{"protocolSection": {"identificationModule": {"nctId": "NCT00507130", "orgStudyIdInfo": {"id": "MI-CP131"}, "secondaryIdInfos": [{"id": "NCT00507130", "type": "REGISTRY", "domain": "ClinicalTrials.gov"}], "organization": {"fullName": "MedImmune LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma", "officialTitle": "A Phase 2A, Randomized, Double-Blind, Placebo-Controlled,Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple-Dose Subcutaneous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody,When Administered to Adults With Mild Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2013-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-07"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-07-23", "studyFirstSubmitQcDate": "2007-07-23", "studyFirstPostDateStruct": {"date": "2007-07-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-10-17", "resultsFirstSubmitQcDate": "2013-10-17", "resultsFirstPostDateStruct": {"date": "2013-12-11", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-09-13", "dispFirstSubmitQcDate": "2012-09-13", "dispFirstPostDateStruct": {"date": "2012-09-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-10-17", "lastUpdatePostDateStruct": {"date": "2013-12-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "MedImmune LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of this study is to evaluate the safety and tolerability of escalating multiple SC doses of MEDI-528 in adult patients with mild persistent asthma.", "detailedDescription": "The secondary objectives of this study are to:\n\n1. Assess the PK of MEDI-528; and\n2. Assess the IM of MEDI-528 in this patient population."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 36, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MEDI528 0.3 mg/kg", "type": "EXPERIMENTAL", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks", "interventionNames": ["Biological: MEDI528 0.3 mg/kg"]}, {"label": "MEDI528 1 mg/kg", "type": "EXPERIMENTAL", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks", "interventionNames": ["Biological: MEDI528 1 mg/kg"]}, {"label": "MEDI528 3 mg/kg", "type": "EXPERIMENTAL", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks", "interventionNames": ["Biological: MEDI528 3 mg/kg"]}, {"label": "PLACEBO", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks", "interventionNames": ["Other: PLACEBO"]}], "interventions": [{"type": "BIOLOGICAL", "name": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks", "armGroupLabels": ["MEDI528 0.3 mg/kg"]}, {"type": "BIOLOGICAL", "name": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks", "armGroupLabels": ["MEDI528 1 mg/kg"]}, {"type": "BIOLOGICAL", "name": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks", "armGroupLabels": ["MEDI528 3 mg/kg"]}, {"type": "OTHER", "name": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks", "armGroupLabels": ["PLACEBO"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Incidence of Adverse Events", "description": "Number of participants experiencing adverse events (includes both adverse events and serious adverse events)", "timeFrame": "Days 0 - 150"}, {"measure": "Incidence of Abnormal Troponin Levels", "description": "Number of participants with troponin levels greater than upper limit of normal", "timeFrame": "Days 0, 14, 28, 56, 84, and 150"}, {"measure": "Incidence of Abnormal Clinically Significant Electrocardiogram (ECG) Results", "description": "Number of participants with abnormal clinically significant ECG results", "timeFrame": "Days -14 to -1, 14, 28, 56, 84, and 150"}, {"measure": "Incidence of Abnormal Clinically Significant Magnetic Resonance Imaging (MRI) Results", "description": "Number of participants experiencing abnormal clinically significant MRI results", "timeFrame": "Days -14 to -1 and 28"}, {"measure": "Incidence of Serious Adverse Events", "description": "Number of participants experiencing serious adverse events", "timeFrame": "Days 0 - 150"}], "secondaryOutcomes": [{"measure": "Incidence of Anti-drug Antibodies (ADA) to MEDI-528", "description": "Number of participants with ADA to MEDI-528", "timeFrame": "Days 0, 28, 56, 84, 119, and 150"}, {"measure": "Time to Observed Maximum Serum Concentration (Tmax)", "description": "Tmax of MEDI-528", "timeFrame": "Days 0, 3, 7, 10, 14, 17, 21, 24, 26, 28, 31, 35, 42, 49, 56, 70, 84, 119, and 150"}, {"measure": "Observed Maximum Serum Concentration (Cmax)", "description": "Cmax of MEDI-528", "timeFrame": "Days 0, 3, 7, 10, 14, 17, 21, 24, 26, 28, 31, 35, 42, 49, 56, 70, 84, 119, and 150"}, {"measure": "Terminal Phase Half-life (T1/2)", "description": "T1/2 of MEDI-528", "timeFrame": "Days 0, 3, 7, 10, 14, 17, 21, 24, 26, 28, 31, 35, 42, 49, 56, 70, 84, 119, and 150"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female adults, age 18 through 65 years of age at time of screening;\n* Weight \u2264 100 kg and body mass index \u2264 35;\n* Written informed consent obtained from the patient prior to receipt of any study medication or beginning study procedures;\n* Previously documented diagnosis of asthma based on episodic symptoms of airflow obstruction such as wheezing or chest tightness, with alternative diagnoses (e.g., chronic obstructive pulmonary disease) ruled out;\n* Currently receiving treatment with short-acting \u03b22 agonists, ICS at doses \u2264 264 \u03bcg/day fluticasone or equivalent, or both (National Heart, Lung, and Blood Institute \\[NHLBI\\], 2002);\n* FEV1 or peak expiratory flow (PEF) \u2265 80% of predictable value;\n* Have had a diagnosis of mild persistent asthma, defined as having asthma symptoms with a frequency of more than twice a week but less than once daily, or nighttime symptoms with a frequency of more than twice a month but less than once a week (NHLBI, 2002);\n* Have AHR based on documented clinical history of either methacholine inhalation challenge with PC20 \u2264 16 mg/mL or partial reversibility of \u2264 12% in FEV1 within the past 18 months (including screening);\n* Able to provide spirometry readings that meet American Thoracic Society/European Respiratory Society standards (Miller, 2005);\n* Sexually active females, unless surgically sterile or at least 1 year post-menopausal, must use an effective method of avoiding pregnancy (including oral, implanted, or transdermal contraceptives, intrauterine device, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 21 days prior to the first dose of study drug, and must agree to continue using such precautions through Study Day 150. Cessation of birth control after this point should be discussed with a responsible physician. Sexually active males, unless surgically sterile, must likewise use an effective method of birth control (condom) and must agree to continue using such precautions through Study Day 150;\n* Ability to complete the study period, including follow-up period, of up to 150 days; and\n* Willing to forego other forms of experimental treatment and study procedures during the study.\n\nExclusion Criteria:\n\n* Receipt of MEDI-528 in any previous clinical study or prior randomization into the trial;\n* History of allergy or reaction to any component of the MEDI-528 formulation;\n* Lung disease other than persistent asthma (e.g. chronic bronchitis);\n* FEV1 \\< 80% of predicted values;\n* History of severe asthma or asthma exacerbation requiring intubation;\n* Use of systemic immunosuppressive drugs including systemic corticosteroids or ICS with doses \\> 264 \u03bcg/day fluticasone or equivalent within 4 weeks prior to Study Day 0;\n* Use of long-acting \u03b22 agonists, theophylline, cromolyn sodium, nedocromil sodium, leukotriene receptor antagonists, or any other inhaled or systemic medication for asthma (except short-acting \u03b22 agonists or ICS at doses \u2264 264 \u03bcg/day fluticasone or equivalent) within the 2 weeks prior to Study Day 0;\n* Current use of any \u03b2-adrenergic antagonist (e.g., propranolol);\n* Any disease or illness, other than asthma, that may require the use of systemic corticosteroids during the study period;\n* Acute illnesses or evidence of significant active infection, such as fever \u2265 38.0\u00b0C (100.5\u00b0F) at screening and up through time of the first dose of study drug;\n* Current allergy vaccination therapy (desensitization immunotherapy), with less than 3 months of stable maintenance doses prior to screening;\n* Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to the first dose of study drug through Study Day 150;\n* Receipt of any therapy with a leukocyte-depleting agent unless recovery in white cell count has been documented before screening;\n* Pregnancy (sexually active females must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to study drug administration on Study Day 0);\n* Lactating or breastfeeding woman;\n* Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus-1 or -2 (HIV-1 or HIV-2), or active infection with hepatitis A;\n* History of significant systemic disease (e.g., cancer, infection, hematological, renal, hepatic, coronary artery disease or other cardiovascular disease, endocrinologic, neurologic, rheumatologic, or gastrointestinal disease);\n* History of cancer other than non-melanoma skin cancer or cervical carcinoma-in-situ treated with apparent success with curative therapy (remission for \u2265 1 year prior to screening);\n* History of primary immunodeficiency;\n* History of pancreatitis;\n* History of use of tobacco products of more than one cigarette per month or equivalent within 1 year prior to randomization or history of smoking of \u2265 10 pack-years;\n* Elective surgery planned during the study period through Study Day 150;\n* Clinically significant abnormalities on physical examination (other than asthma) prior to the first dose of study drug (including but not limited to splenomegaly); Clinically significant abnormality, as determined by the investigator, on 12-lead ECG, MRI, or chest radiograph at the time of screening;\n* At the time of screening, any abnormality of the following measurements: hemoglobin, total white blood cell count (WBC), platelet count, aspartate transaminase (AST), alanine transaminase (ALT), amylase, or serum creatinine above the upper limits of normal (ULN); or other abnormal laboratory values in the screening panel that, in the opinion of the principal investigator, are judged to be clinically significant;\n* Evidence of any systemic disease or respiratory disease (other than asthma), any finding upon physical examination or history of any disease that, in the opinion of the investigator or medical monitor, may compromise the safety of the patient in the study or confound the analysis of the study; or\n* Employees of the clinical study site or any other individuals involved with the conduct of the study, or family members of such individuals.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Joe Parker, M.D.", "affiliation": "MedImmune LLC", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Colorado Allergy & Asthma Centers, PC", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Northeast Medical Research Associates, Inc.", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Clinical Research Institute, Inc.", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "North Carolina Clinical Research", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Toledo Center for Clinical Research", "city": "Sylvania", "state": "Ohio", "zip": "43560", "country": "United States", "geoPoint": {"lat": 41.71894, "lon": -83.71299}}, {"facility": "Spartanburg Medical Research", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "McMaster University", "city": "Hamilton", "state": "Ontario", "zip": "L8N 3Z5", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al", "city": "Montr\u00e9al", "state": "Quebec", "zip": "H4J 1C5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Hopital Laval", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}]}, "referencesModule": {"references": [{"pmid": "21356110", "type": "DERIVED", "citation": "Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA; MEDI-528 Clinical Trials Group. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011 Feb 28;11:14. doi: 10.1186/1471-2466-11-14."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Treatment assignments were determined using a block randomization procedure at a 3:1 active treatment-to-placebo ratio through an interactive voice response system (IVRS). When a subject was assigned a Participant Identification Number by the IVRS, the subject was considered randomized into the study.", "recruitmentDetails": "A total of 36 subjects were entered into the study between 28Jun2007 and 17Jul2008 at 8 sites in the United States of America (5 sites) and Canada (3 sites).", "groups": [{"id": "FG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "FG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "FG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "FG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "SERIOUS EVENT OF ASTHMA EXACERBATION", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "BG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "BG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "BG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "36"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.6", "spread": "13.2"}, {"groupId": "BG001", "value": "38.2", "spread": "16.3"}, {"groupId": "BG002", "value": "33.2", "spread": "11.9"}, {"groupId": "BG003", "value": "28.9", "spread": "10.7"}, {"groupId": "BG004", "value": "34.7", "spread": "13.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "26"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "10"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Incidence of Adverse Events", "description": "Number of participants experiencing adverse events (includes both adverse events and serious adverse events)", "populationDescription": "All subjects who received at least one dose of investigational product (MEDI-528 or placebo)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Days 0 - 150", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "OG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}]}]}, {"type": "PRIMARY", "title": "Incidence of Abnormal Troponin Levels", "description": "Number of participants with troponin levels greater than upper limit of normal", "populationDescription": "All subjects who received at least one dose of investigational product (MEDI-528 or placebo)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Days 0, 14, 28, 56, 84, and 150", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "OG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}]}, {"type": "PRIMARY", "title": "Incidence of Abnormal Clinically Significant Electrocardiogram (ECG) Results", "description": "Number of participants with abnormal clinically significant ECG results", "populationDescription": "All subjects who received at least one dose of investigational product (MEDI-528 or placebo)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Days -14 to -1, 14, 28, 56, 84, and 150", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "OG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Incidence of Abnormal Clinically Significant Magnetic Resonance Imaging (MRI) Results", "description": "Number of participants experiencing abnormal clinically significant MRI results", "populationDescription": "All subjects who received at least one dose of investigational product (MEDI-528 or placebo)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Days -14 to -1 and 28", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "OG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Incidence of Serious Adverse Events", "description": "Number of participants experiencing serious adverse events", "populationDescription": "All subjects who received at least one dose of investigational product (MEDI-528 or placebo)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Days 0 - 150", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "OG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Incidence of Anti-drug Antibodies (ADA) to MEDI-528", "description": "Number of participants with ADA to MEDI-528", "populationDescription": "All subjects who received at least one dose of MEDI-528", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Days 0, 28, 56, 84, 119, and 150", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "OG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Time to Observed Maximum Serum Concentration (Tmax)", "description": "Tmax of MEDI-528", "populationDescription": "All subjects who received at least one dose of MEDI-528 and had blood samples analyzed for pharmacokinetic analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Day", "timeFrame": "Days 0, 3, 7, 10, 14, 17, 21, 24, 26, 28, 31, 35, 42, 49, 56, 70, 84, 119, and 150", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "OG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "3.5", "spread": "2.1"}, {"groupId": "OG002", "value": "3.7", "spread": "2.3"}, {"groupId": "OG003", "value": "3.9", "spread": "2.6"}]}]}]}, {"type": "SECONDARY", "title": "Observed Maximum Serum Concentration (Cmax)", "description": "Cmax of MEDI-528", "populationDescription": "All subjects who received at least one dose of MEDI-528 and had blood samples analyzed for pharmacokinetic analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Micrograms per milliliter", "timeFrame": "Days 0, 3, 7, 10, 14, 17, 21, 24, 26, 28, 31, 35, 42, 49, 56, 70, 84, 119, and 150", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "OG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "13.7", "spread": "2.7"}, {"groupId": "OG002", "value": "52.1", "spread": "33.0"}, {"groupId": "OG003", "value": "105.5", "spread": "31.0"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Phase Half-life (T1/2)", "description": "T1/2 of MEDI-528", "populationDescription": "All subjects who received at least one dose of MEDI-528 and had blood samples analyzed for pharmacokinetic analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Day", "timeFrame": "Days 0, 3, 7, 10, 14, 17, 21, 24, 26, 28, 31, 35, 42, 49, 56, 70, 84, 119, and 150", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks"}, {"id": "OG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks"}, {"id": "OG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "37.1", "spread": "7.5"}, {"groupId": "OG002", "value": "35", "spread": "11.5"}, {"groupId": "OG003", "value": "37.7", "spread": "7.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "PLACEBO", "description": "Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 9, "otherNumAffected": 9, "otherNumAtRisk": 9}, {"id": "EG001", "title": "MEDI528 0.3 mg/kg", "description": "MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a SC dose for 4 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 9, "otherNumAtRisk": 9}, {"id": "EG002", "title": "MEDI528 1 mg/kg", "description": "MEDI-528 at a dose of 1 mg/kg administered twice weekly as a SC dose for 4 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 9, "otherNumAtRisk": 9}, {"id": "EG003", "title": "MEDI528 3 mg/kg", "description": "MEDI-528 at a dose of 3 mg/kg administered twice weekly as a SC dose for 4 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 9, "otherNumAtRisk": 9}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}], "otherEvents": [{"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Chills", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}]}, {"term": "Injection site bruising", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 9}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 8, "numAffected": 3, "numAtRisk": 9}]}, {"term": "Injection site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Injection site urticaria", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Vessel puncture site haematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Immunisation reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Tooth abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 3, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 3, "numAffected": 2, "numAtRisk": 9}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Vulvovaginal mycotic infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Arthropod bite", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Subcutaneous haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Blood amylase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Blood bicarbonate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 5, "numAffected": 3, "numAtRisk": 9}]}, {"term": "Blood bicarbonate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Blood chloride decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Blood chloride increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Blood glucose decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 8, "numAffected": 5, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 5, "numAffected": 3, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 3, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Blood potassium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Blood potassium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Blood urea increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Blood urine present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "False positive laboratory result", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 4, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 3, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 6, "numAffected": 4, "numAtRisk": 9}]}, {"term": "Haemoglobin decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Lipase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Lymphocyte count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Neutrophil count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Neutrophil count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Protein urine present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Red blood cells urine positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "White blood cell count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 5, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 2, "numAffected": 1, "numAtRisk": 9}]}, {"term": "White blood cell count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "White blood cells urine positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Musculoskeletal discomfort", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Torticollis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Panic attack", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Proteinuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Pharyngolaryngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Postnasal drip", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Respiratory tract congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Dermal cyst", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Rash papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 2, "numAffected": 1, "numAtRisk": 9}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication."}, "pointOfContact": {"title": "Don Raible, MD", "organization": "MedImmune", "email": "raibleD@medimmune.com", "phone": "301-398-0000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}